Skip to main content

IP Roundup: Fluidigm, Korea Institute of Science and Technology, Illumina


Fluidigm of South San Francisco, Calif., has received US Patent No. 8,420,017, "Microfluidic reaction apparatus for high-throughput screening." The microfluidic device described has a slug mixing arrangement, where the reaction well has an input flow channel with a first valve near the well, and a second valve further from the well. A fluid source is connected to the segment in between the two valves. A second fluid source is connected behind the second valve. According to the patent, the channel between the two valves receives the first fluid by blind filling when the valves are closed, while the reaction well receives the first fluid followed by the second fluid when the valves are open.

Korea Institute of Science and Technology of Seoul has received US Patent No. 8,420,181, "Method of producing microfluidic devices based on a polymer." The method includes forming a microstructure on a lower polymer matrix; coating the lower polymer matrix; bonding the lower polymer matrix with an upper polymer matrix; and radiating UV lights to convert the coated regions into hydrophilic regions. A polymer-based microfluidic device obtained by the method is also described.

Illumina of San Diego has received US Patent No. 8,422,031, "Focusing methods and optical systems and assemblies using the same." The method includes providing a pair of incident light beams to a conjugate lens. The incident light beams are directed by the lens to converge toward a focal region. The method also includes reflecting the incident light beams with an object positioned proximate to the focal region. The reflected light beams return to and propagate through the lens. Additionally, the method includes determining relative separation measured between the reflected light beams and determining a degree-of-focus of the optical system with respect to the sample based upon the relative separation.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.